Head-To-Head Contrast: Abattis Bioceuticals (OTCMKTS:ATTBF) versus Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Zentalis Pharmaceuticals and Abattis Bioceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1	4	4	0	2.33
Abattis Bioceuticals	0	0	0	0	0.00

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 62.65%. Given Zentalis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Zentalis Pharmaceuticals is more favorable than Abattis Bioceuticals.

Earnings & Valuation

This table compares Zentalis Pharmaceuticals and Abattis Bioceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43 million	4.41	-$137.06 million	($1.95)	-2.13
Abattis Bioceuticals	N/A	N/A	N/A	($0.16)	N/A

Abattis Bioceuticals has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Abattis Bioceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

32.5% of Abattis Bioceuticals shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zentalis Pharmaceuticals and Abattis Bioceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%
Abattis Bioceuticals	N/A	N/A	N/A

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Abattis Bioceuticals

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.